EUVIMEDEUVIMED entdecken
Crossref

Exploring the potential therapeutic significance of secukinumab for annular epidermolytic ichthyosis

Yue Zhang, Gang Chen, Mengxing Cui, Guiyuan Zhang, Hequn Huang, Ming Li, Bo Liang

European Journal of Dermatology · 2026-11 · 36 (6) · 00-00

DOI: 10.1684/ejd.2026.5184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Dermatology, 2026-11. Verfasst von Yue Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, the First Affiliated Hospital of Anhui Medical University, Hefei230000, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

IL-17AKRT1annular epidermolytic ichthyosisepidermolytic ichthyosissecukinumab

Autor:innen und Institutionen

  • Department of Clinical Laboratory, the First Affiliated Hospital of Anhui Medical University, Hefei230000, China.
  • Department of Dermatology, Children's Hospital Affiliated to Fudan University, National Children's Medical Center, Shanghai, China.

Zitieren

APA

Zhang, Y., Chen, G., Cui, M., Zhang, G., Huang, H., Li, M., & Liang, B. (2026). Exploring the potential therapeutic significance of secukinumab for annular epidermolytic ichthyosis. European Journal of Dermatology, 36(6), 00-00. https://doi.org/10.1684/ejd.2026.5184

Vancouver

Zhang Y, Chen G, Cui M, Zhang G, Huang H, Li M, et al. Exploring the potential therapeutic significance of secukinumab for annular epidermolytic ichthyosis. European Journal of Dermatology. 2026;36(6):00-00. doi:10.1684/ejd.2026.5184

BibTeX
@article{Zhang2026,
  author = {Zhang, Yue and Chen, Gang and Cui, Mengxing and Zhang, Guiyuan and Huang, Hequn and Li, Ming and Liang, Bo},
  title = {Exploring the potential therapeutic significance of secukinumab for annular epidermolytic ichthyosis},
  journal = {European Journal of Dermatology},
  year = {2026},
  volume = {36},
  number = {6},
  pages = {00--00},
  doi = {10.1684/ejd.2026.5184}
}
Kostenlos starten →